Interpace Diagnostics Group, Inc. (75) | Business Finance (33)

Browse by Subcategory

Recent Contracts

First Amendment to Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation,... (Filed With SEC on May 10, 2022)
First Amendment to Loan and Security Agreement and Consent with BroadOak Fund V, L.P. dated May 5, 2022 between Interpace Biosciences, Inc., Interpace Diagnostics Corporation,... (Filed With SEC on May 10, 2022)
Subordinated Convertible Promissory Note to BroadOak Fund V, L.P., dated May 5, 2022 (Filed With SEC on May 10, 2022)
Form of Investor Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, to be entered into at the closing of the Standby Purchase Commitment (Filed With SEC on January 3, 2022)
Form of Registration Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, to be entered into at the closing of the Standby Purchase Commitment (Filed With SEC on January 3, 2022)
Form of Standby Purchase Agreement by and among Interpace Biosciences, Inc., 3K Limited Partnership, Peter H. Kamin, Peter H. Kamin Revocable Trust dated February 2003, Peter H.... (Filed With SEC on January 3, 2022)
Form of Subscription Rights Certificate (Filed With SEC on January 3, 2022)
Amendment to Security Agreement dated May 10, 2021 by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc (Filed With SEC on August 11, 2021)
Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc (Filed With SEC on April 22, 2020)
Form of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (included as Exhibit A to the Securities Purchase and Exchange... (Filed With SEC on January 14, 2020)
Interpace Biosciences, Inc. Employee Stock Purchase Plan (Filed With SEC on November 14, 2019)
Equity Distribution Agreement, dated September 20, 2019, by and between Interpace Diagnostics Group, Inc. and Oppenheimer & Co. Inc (Filed With SEC on September 20, 2019)
Form of Underwriter Common Stock Purchase Warrant (Filed With SEC on January 29, 2019)
Underwriting Agreement, dated as of January 25, 2019, by and between Interpace Diagnostics Group, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on January 29, 2019)
Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace... (Filed With SEC on November 3, 2021)
First Amendment to Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and... (Filed With SEC on November 3, 2021)
Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma... (Filed With SEC on November 3, 2021)
Subordination Agreement by and between Ampersand 2018 Limited Partnership, 1315 Capital II. L.P., Comerica Bank Interpace Biosciences, Inc., Interpace Diagnostics Corporation,... (Filed With SEC on October 19, 2021)
Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma... (Filed With SEC on October 19, 2021)
Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P (Filed With SEC on August 11, 2021)
Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership (Filed With SEC on August 11, 2021)
Security Agreement entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021, . Upon the request of the SEC, the Company agrees to furnish copies of the... (Filed With SEC on May 11, 2021)
Joinder and Second Loan Modification Agreement, dated October 19, 2020, by and among the Company, Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma... (Filed With SEC on October 23, 2020)
First Loan Modification Agreement, dated March 18, 2019, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc. (n/k/a Interpace Biosciences, Inc.), Interpace... (Filed With SEC on October 19, 2020)
Loan and Security Agreement, dated November 13, 2018, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, and Interpace... (Filed With SEC on April 22, 2020)
Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership (Filed With SEC on January 17, 2020)
Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
Investor Rights Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Securities Purchase Agreement, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Ampersand 2018 Limited Partnership (Filed With SEC on July 19, 2019)
Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)